Nicox's Enterprise Value for the quarter that ended in Jun. 2023 was $34.24 Mil.
Nicox's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-17.56 Mil. Nicox's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2023 was 0.00%.
The historical rank and industry rank for Nicox's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
NICXF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -371.8 Med: -15.91 Max: -2.4
Current: -76.34
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Nicox was -2.40%. The lowest was -371.80%. And the median was -15.91%.
NICXF's Earnings Yield (Joel Greenblatt) % is ranked worse than 80.6% of 1397
companies
in the Biotechnology industry
Industry Median: -15.77
vs NICXF: -76.34
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Nicox's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Nicox Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Nicox's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Nicox Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Earnings Yield (Joel Greenblatt) %
-15.63
-18.28
-11.93
-50.51
-57.47
Nicox Semi-Annual Data
Dec13
Jun14
Dec14
Jun15
Dec15
Jun16
Dec16
Jun17
Dec17
Jun18
Dec18
Jun19
Dec19
Jun20
Dec20
Jun21
Dec21
Jun22
Dec22
Jun23
Earnings Yield (Joel Greenblatt) %
-
-50.51
-
-57.47
-
Competitive Comparison
For the Biotechnology subindustry, Nicox's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nicox Earnings Yield (Joel Greenblatt) % Distribution
For the Biotechnology industry and Healthcare sector, Nicox's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Nicox's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Nicoxs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2022 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Nicox Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Nicox's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NICXF has been successfully added to your 